In New York City, Peter Tunney's billboard greets you as you enter the Midtown Tunnel: “Welcome to the CITY OF DREAMS” and ushers you out with a “You are now leaving the CITY OF DREAMS.”
NCI will bump up the budget for its Research Project Grant pool by $100 million in 2018—the largest increase to the institute's RPG pool since 2003, NCI Director Norman “Ned” Sharpless said at the annual meeting of the American Association for Cancer Research in Chicago.
NCI's Research Project Grant pool is likely to receive the largest increase in funding in 16 years, NCI Director Norman “Ned” Sharpless said at an NCI Town Hall meeting April 10.
Congress has been good to biomedical research over the past three years.
Photo courtesy of Research!AmericaThe Research!America 2018 Advocacy Awards Dinner at the Andrew W. Mellon Auditorium March 14On March 14, beneath the soaring ceiling of the Andrew W. Mellon Auditorium, Rep. Nancy Pelosi (D-CA) faced a constellation of round tables at the Research!America 2018 Advocacy Awards Dinner.
Few Washington insiders doubt that a bill that allows terminally ill patients to circumvent FDA as they pursue Hail Mary pass therapies will become the law of the land.
Researchers are coming to the conclusion that cancer patients are the best authority on how therapies affect them.
The FDA Oncologic Drugs Advisory Committee March 7 voted to accept the metric of “minimal residual disease,” or MRD, as a basis for approval of a drug for the treatment of acute lymphoblastic leukemia.
Roche has signed an agreement to acquire all shares of Flatiron Health, a health care technology and services company headquartered in New York City, for $1.9 billion.
“The notion that cancer's not one disease, but thousands of diseases is really starting to sink in, and the implications of that fact are being felt throughout [NCI], and it means we have to change how we do everything. I hope that the early days of the Sharpless administration will be remembered as a time when we really bought into that reality and did some things differently,” NCI Director Norman “Ned” Sharpless said in a conversation with The Cancer Letter.
